scholarly article | Q13442814 |
P50 | author | Stian Knappskog | Q55136879 |
Inger Torhild Gram | Q114340583 | ||
Ranjan Chrisanthar | Q117267020 | ||
Johan Richard Lillehaug | Q125223686 | ||
Anne-Lise Børresen-Dale | Q11958220 | ||
Per Eystein Lønning | Q11995192 | ||
P2093 | author name string | Vidar Staalesen | |
P2860 | cites work | p21 expression and mutation in gastric carcinoma: analysis by immunohistochemistry and PCR-SSCP. | Q34656213 |
Lack of evidence of association of p21WAF1/CIP1 polymorphism with lung cancer susceptibility and prognosis in Taiwan | Q46846464 | ||
P433 | issue | 4 | |
P407 | language of work or name | English | Q1860 |
P1104 | number of pages | 3 | |
P304 | page(s) | 908-910 | |
P577 | publication date | 2007-08-01 | |
P1433 | published in | International Journal of Cancer | Q332492 |
P1476 | title | Mutations and polymorphisms of the p21B transcript in breast cancer | |
P478 | volume | 121 |
Q51165773 | Association of mutation and hypermethylation of p21 gene with susceptibility to breast cancer: a study from north India. |
Q40907746 | Concomitant inactivation of the p53- and pRB- functional pathways predicts resistance to DNA damaging drugs in breast cancer in vivo |
Q42049244 | Elevated levels of the steroidogenic factor 1 are associated with over-expression of CYP19 in an oestrogen-producing testicular Leydig cell tumour |
Q33615319 | Genetic polymorphisms of p21 and risk of second primary malignancy in patients with index squamous cell carcinoma of the head and neck |
Q34013967 | Identification and characterization of retinoblastoma gene mutations disturbing apoptosis in human breast cancers |
Q36245541 | Low expression levels of ATM may substitute for CHEK2 /TP53 mutations predicting resistance towards anthracycline and mitomycin chemotherapy in breast cancer |
Q44248155 | MDM2 and CDKN1A gene polymorphisms and risk of Kaposi's sarcoma in African and Caucasian patients |
Q38087850 | Mapping genetic alterations causing chemoresistance in cancer: identifying the roads by tracking the drivers |
Q37039810 | Strength and weakness of phase I to IV trials, with an emphasis on translational aspects |
Search more.